DK3749308T3 - Behandling af patienter med klassisk fabrys sygdom med migalastat - Google Patents

Behandling af patienter med klassisk fabrys sygdom med migalastat Download PDF

Info

Publication number
DK3749308T3
DK3749308T3 DK19706182.3T DK19706182T DK3749308T3 DK 3749308 T3 DK3749308 T3 DK 3749308T3 DK 19706182 T DK19706182 T DK 19706182T DK 3749308 T3 DK3749308 T3 DK 3749308T3
Authority
DK
Denmark
Prior art keywords
migalastat
patients
disease
treatment
classic fabry
Prior art date
Application number
DK19706182.3T
Other languages
Danish (da)
English (en)
Inventor
Jay Barth
Elfrida Benjamin
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3749308(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK3749308T3 publication Critical patent/DK3749308T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK19706182.3T 2018-02-06 2019-02-06 Behandling af patienter med klassisk fabrys sygdom med migalastat DK3749308T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease

Publications (1)

Publication Number Publication Date
DK3749308T3 true DK3749308T3 (da) 2024-01-22

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19706182.3T DK3749308T3 (da) 2018-02-06 2019-02-06 Behandling af patienter med klassisk fabrys sygdom med migalastat

Country Status (20)

Country Link
US (1) US20210038579A1 (enExample)
EP (2) EP4316589A3 (enExample)
JP (2) JP2021512896A (enExample)
KR (1) KR20200128675A (enExample)
CN (1) CN112203657A (enExample)
AR (1) AR114392A1 (enExample)
AU (2) AU2019217603A1 (enExample)
DK (1) DK3749308T3 (enExample)
ES (1) ES2969263T3 (enExample)
FI (1) FI3749308T3 (enExample)
HR (1) HRP20240025T1 (enExample)
HU (1) HUE064761T2 (enExample)
LT (1) LT3749308T (enExample)
PL (1) PL3749308T3 (enExample)
PT (1) PT3749308T (enExample)
RS (1) RS65103B1 (enExample)
SI (1) SI3749308T1 (enExample)
SM (1) SMT202400027T1 (enExample)
TW (1) TWI869336B (enExample)
WO (1) WO2019157056A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
JP2024525760A (ja) * 2021-07-12 2024-07-12 アミカス セラピューティックス インコーポレイテッド 小児患者のファブリー病を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX351004B (es) * 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
WO2018017721A1 (en) * 2016-07-19 2018-01-25 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
EA202090242A1 (ru) * 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов

Also Published As

Publication number Publication date
EP3749308A1 (en) 2020-12-16
SI3749308T1 (sl) 2024-03-29
HRP20240025T1 (hr) 2024-03-29
FI3749308T3 (fi) 2024-01-18
AU2025200074A1 (en) 2025-01-30
WO2019157056A8 (en) 2020-12-03
PT3749308T (pt) 2024-01-25
EP4316589A3 (en) 2024-04-24
KR20200128675A (ko) 2020-11-16
US20210038579A1 (en) 2021-02-11
EP3749308B1 (en) 2023-10-25
TW201944998A (zh) 2019-12-01
AU2019217603A1 (en) 2020-09-24
SMT202400027T1 (it) 2024-03-13
CN112203657A (zh) 2021-01-08
CA3090499A1 (en) 2019-08-15
ES2969263T3 (es) 2024-05-17
TWI869336B (zh) 2025-01-11
PL3749308T3 (pl) 2024-03-25
EP4316589A2 (en) 2024-02-07
JP2024026080A (ja) 2024-02-28
TW202537622A (zh) 2025-10-01
RS65103B1 (sr) 2024-02-29
HUE064761T2 (hu) 2024-04-28
AR114392A1 (es) 2020-09-02
LT3749308T (lt) 2024-02-12
WO2019157056A1 (en) 2019-08-15
JP2021512896A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
IL281773A (en) Ophthalmic composition for treatment of dry eye disease
IL271046A (en) Compounds for treating huntington's disease
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
MX394462B (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS.
IL284414A (en) Methods and compositions for the treatment of fabry disease
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
HUE064761T2 (hu) Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
EP3528852A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS FABRY
HUE071155T2 (hu) Biszkolin-tetratiomolibdát Wilson-kór kezelésére
DK3773558T3 (da) Kombinationsbehandling af artritisk sygdom
DK3700529T3 (da) Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild)
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
IL269083A (en) Methods for preventing and treating heart disease
EP3606535A4 (en) TREATMENT OF INFLAMMATORY INTESTINAL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep
IL281244A (en) Combination therapy for the treatment of liver disease
LT3463351T (lt) Parkinsono ligos gydymas
EP3833435A4 (en) DETERMINATION OF PARKINSON'S DISEASE
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
DK3416654T3 (da) Medicinsk anvendelse af 5'-adenosindiphosphatribose (adpr)
DK3761982T3 (da) Anvendelse af nalfurafin til behandling af demyeliniserende sygdomme
DK3863647T3 (da) Behandling af ondartet knoglesmerte med pentosanpolysulfat
EP3630114B9 (en) MIGALASTAT FOR THE TREATMENT OF PATIENTS WITH FABRY DISEASE SUFFERING FROM KIDNEY FAILURE
IL286818A (en) Mirikizumab for use in a method of treating crohns disease
IL288793A (en) Compounds for treating respiratory disease